Back to top

Regenxbio price target raised to $18 from $16 at Morgan Stanley

Morgan Stanley analyst Judah Frommer raised the firm’s price target on Regenxbio (RGNX) to $18 from $16 and keeps an Overweight rating on the share...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

REGENXBIO Inc. (RGNX)